Politics and Policy Survey

One result of the Inflation Reduction Act shifting a greater proportion the cost of drugs during the catastrophic phase of coverage to the Part D plans result may be narrower formularies.

Adam Colborn outlined four trends in state-level action on pharmacy benefit managers (PBMs) and drugs in an interview prior to this presentation at the annual meeting of Academy of Managed Care Pharmacy (AMCP) today.

In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.

A group of researchers recently aimed to investigate the prognosis of patients with NSCLC that lacked a spouse, family members, or friends to support them during cancer treatment.

Panelists discussed reaching beyond large patient advocacy groups for input and how clinical trial endpoints may paint an incomplete picture of a drug's true value to patients.